This page was reviewed but not written by the grant investigators. VST Bio staff also reviewed this page prior to publication.
Open Philanthropy recommended an investment of $4,500,000 in VST Bio to develop a novel treatment for stroke and traumatic brain disease. Stroke is the second most common cause of death worldwide and the third most common cause of disability. Currently, there are no drugs that reduce the brain damage caused by acute stroke. Following our March 2019 support to Yale University, researchers developed antibodies that significantly reduce the brain damage caused by stroke in mice. This seed-stage investment is intended to support additional research and development in the hopes that VST Bio can subsequently raise additional funds from other investors to conduct a clinical trial of the treatment in humans.
This page was reviewed but not written by the grant investigators. Kainomyx staff also reviewed this page prior to publication.
Open Philanthropy recommended an investment of $1,999,999 in Kainomyx to develop and produce a new antimalarial drug. If effective, the new drug would act by inhibiting cytoskeletal proteins in malarial parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing artemisinin resistance to existing treatments.
This page was reviewed but not written by the grant investigators. Sherlock Biosciences staff also reviewed this page prior to publication.
The Open Philanthropy Project recommended a grant of up to $17,500,000 over five years and an additional investment in Sherlock Biosciences to support the development of a diagnostic platform to quickly, easily, and inexpensively identify any human virus present in a patient sample. Development of this technology would represent a significant advance in viral diagnosis, and could both reduce threats from viral pandemics and also benefit health care broadly. Sherlock recently spun out of Harvard University’s Wyss Institute and the Broad Institute of MIT and Harvard.
This page was reviewed but not written by the grant investigators. EicOsis staff also reviewed this page prior to publication.
The Open Philanthropy Project recommended an investment of $5,000,000 in EicOsis to support clinical trials on a novel, non-opioid, oral therapy for neuropathic and inflammatory pain. Chronic pain affects as many as 100 million people in the U.S. alone, and total costs for treating pain have been estimated to be as high as $635 billion annually.Source: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research We believe alternate therapies for chronic pain could help address the epidemic of opioid abuse and addiction. EicOsis previously received Blueprint funding for neuroscience research from the National Institutes of Health. This seed-stage investment is intended to support continued early research and development in the hopes that EicOsis can subsequently raise additional funds from other investors.
This page was reviewed but not written by the grant investigators. Representatives of VasoRX reviewed this page prior to publication.
The Open Philanthropy Project recommended an investment of $5,400,000 in VasoRX to test a new therapy for vascular diseases such as atherosclerosis and pulmonary hypertension. Atherosclerosis, a disease in which arteries narrow due to the buildup of plaque, leads to heart attacks and strokes and is one of the leading causes of death in the developed world. Researchers have been able to suppress a protein believed to contribute to atherosclerosis in mice. This seed-stage investment is intended to support additional research and development in the hopes that VasoRx can subsequently raise additional funds from other investors to conduct a clinical trial of the therapy in humans.
Impossible Foods staff reviewed this page prior to publication.
The Open Philanthropy Project has invested in Impossible Foods (IF) to accelerate the development of plant-based meats.
Limited disclosure
IF asked us not to disclose a number of important pieces of information related to this investment because IF is a for-profit, privately held startup company with a significant portfolio of intellectual property. Therefore, we have not gone into as much detail as we otherwise would.
In particular, we agreed with IF not to publicly disclose the terms of the investment, which products we have seen or tasted at IF’s headquarters, or any information about specific scientific and technical challenges that IF’s team is working to overcome.
Background
The Open Philanthropy Project invested in IF as part of our work on farm animal welfare.
IF is a Silicon Valley-based technology startup that develops meat directly from plants. IF launched its first product, the Impossible Burger, in July 2016. The Impossible Burger is now on the menu of eleven restaurants across the U.S. IF is constructing a factory in California that, when fully ramped up in the second half of 2017, will increase supply of the Impossible Burger to restaurants throughout the United States.
While in the near term IF remains focused on the successful commercialization of the Impossible Burger as its flagship product, IF’s longer-term plans include development and commercialization of additional plant-based products to compete with all the foods that today are produced using animals in all major regions globally.
Since its founding in 2011, IF’s team of scientists has done advance research and development (R&D) on different products including ground and whole-cut beef, pork, chicken, fish, and dairy and cheese products. With our new investment, we hope to accelerate the development and commercialization of a second wave of plant-based foods, enabling IF to expand from the Impossible Burger to additional product categories.
Case for investment
In rough outline, we arrived at a decision to make this investment as follows:
Farm animal welfare is one of our focus areas. We specifically wanted to invest in people who are working on plant-based alternatives to chicken, eggs and fish because very large numbers of animals are negatively affected by current practices related to producing these foods.
We have chosen not to prioritize investment in R&D for cultured meat, especially for whole-cut meat (i.e. not ground meat) because we believe technical tractability is currently low (particularly with respect to getting costs acceptably low).
We were interested in someone using a bioengineering-based approach, analogous to what IF has done with the Impossible Burger, to develop plant-based alternatives to chicken, eggs, and fish. We were particularly interested in IF’s approach based on:
our Scientific Advisor Chris Somerville’s opinion that Pat Brown (IF’s Founder and CEO) is an outstanding scientist;
a belief that technical barriers to a viable, low-cost product in this area are much smaller than technical barriers to developing whole-cut cultured meat;
a belief that more science-heavy/bioengineering-oriented approaches were more likely to yield a transformative product than other attempts to develop plant-based alternatives;
a taste test of the Impossible Burger, which we believe is a promising product.
We were aware of the Impossible Burger and IF’s investments from venture capital firms, Google Ventures, Bill Gates and others. We decided to ask IF if it would be interested in working on whole-cut chicken in particular, or whether it could help us find someone else to work on chicken.
IF told us that it could apply an investment to accelerate its work on the development of specific food categories. IF presented us with several scenarios in which the IF teams would work on one or more food categories.
After a review of IF’s long-term product plan, interviews with key scientists and executives, and reviews with our financial advisors, we opted for an investment with the intention of accelerating the development of multiple food categories.
We agreed informally with IF’s senior executives that IF would use Open Philanthropy’s investment to accelerate commercialization of multiple food categories.
Plans for follow-up
We hope that our investment will accelerate the development and commercialization of key products by a few years. We plan to meet with IF every 6 to 12 months over the next two years to check on IF’s progress.
Key questions for follow-up include:
Is IF’s work toward the development of new categories of plant-based meat proceeding according to schedule?
How much scientific effort is directed toward each new food category? Is that in line with plans?
How much progress has been made on technical challenges or other potential roadblocks to commercialization?
Did IF’s cost of production per pound of ground beef decrease as anticipated?
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.